FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Employees Told Not to Use Claude AI in Tech Dispute

[ Price : $8.95]

HHS directs FDA and other health agency employees to immediately stop using the artificial intelligence platform Claude after the ...

Synergy Spines Artificial Cervical Disc Approved

[ Price : $8.95]

FDA approves a Synergy Spine Solutions PMA for its Synergy Disc, a motion-preserving artificial cervical disc.

Researcher Critiques FDA Minimal Residual Disease Guidance

[ Price : $8.95]

A leading myeloma researcher says FDAs draft guidance endorsing minimal residual disease as a potential basis for accelerated drug...

User Fee Negotiations Are Hung Up on America First Proposals

[ Price : $8.95]

Drug user fee negotiators confront lingering divisions over FDAs America First proposals and the structure of hiring commitments, ...

DoJ Supports Generic Drug Skinny Label Provision

[ Price : $8.95]

The U.S. Department of Justice (DoJ) says a Federal Circuit ruling on so-called generic drug skinny labels threatens to undermine ...

Rare Disease Developers Welcome FDA Guidance

[ Price : $8.95]

Rare disease drug developers and patient advocates are applauding a series of new guidance documents from FDA that bring long-awai...

Senate Committee Presses Pentagon Over FDA Import Exemptions

[ Price : $8.95]

The U.S. Senate Special Committee on Aging raises concerns about FDAs handling of foreign drug manufacturing violations and how th...

Ionis' Olezarsen Priority Review for Severe Hypertriglyceridemia

[ Price : $8.95]

FDA accepts for priority review an Ionis Pharmaceuticals supplemental NDA for olezarsen for treating severe hypertriglyceridemia.

Lillys Oral GLP-1 Orforglipron Beats Oral Semaglutide in Trial

[ Price : $8.95]

Eli Lilly reports favorable efficacy data on its investigational oral GLP-1 receptor agonist orforglipron, showing significantly g...

Makary Defends Approval Standards and Prasads Role

[ Price : $8.95]

FDA commissioner Marty Makary defends the agencys scientific standards and personnel, particularly CBER director Vinay Prasad, ami...